Saturday 17 October 2026
Export BIORQ’s income statement to Excel — free account
Biora Therapeutics, Inc.
BIORQ Healthcare Biotechnology
Operating cash flow growth for three consecutive years.
0.00
0.00
NaN
Follow BIORQ
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | |
|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 4 | 3 | 2 | 2 |
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | (6.45) | (12.67) | (25.00) | (51.34) |
P/S ratio |
— | 0.58 | 0.58 | 7.64 | 278.35 | 58.83 | 214.06 |
Altman Z″-Score (non-manufacturers) |
— | (16.82) | (22.55) | (14.26) | (29.12) | (56.99) | (123.80) |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | — | (2.88) | 158.57 | 1.97 | 2.99 | 42.05 |
P/Operating CF |
— | (2.12) | (2.12) | (3.70) | (8.67) | (1.63) | (1.53) |
P/B ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
— | 1.12 | 1.12 | 9.63 | 308.82 | 380.85 | 525.30 |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | (0.92) | (0.92) | (1.99) | (2.30) | (1.80) | (1.06) |
EV/FCF |
— | (0.89) | (0.89) | (1.95) | (2.29) | (1.78) | (1.06) |
Quick Ratio |
— | 0.99 | 0.56 | 1.36 | 1.45 | 1.34 | 0.25 |
Current Ratio |
— | 1.14 | 0.74 | 1.74 | 1.60 | 1.64 | 0.30 |
Net Debt/EBITDA |
— | (0.03) | 0.22 | (0.67) | (0.33) | (1.65) | (0.47) |
Debt/Assets |
0.00% | 62.49% | 3.62% | 103.78% | 116.14% | 240.46% | 146.44% |
Debt/Equity |
— | (1.97) | (0.04) | (1.50) | (1.49) | (1.26) | (0.45) |
Asset Turnover |
— | 2.20 | 1.32 | 0.00 | 0.01 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.50 | 0.46 | 0.86 | 0.68 | 1.69 | 0.39 |
Capex/Depreciation |
— | 0.00 | (0.59) | (0.76) | (0.28) | (0.34) | (0.04) |
Interest Coverage |
— | (20.98) | (15.23) | (10.78) | (9.33) | (5.62) | (6.84) |
| — | 213.45% | 378.33% | 201.91% | 257.76% | 40.75% | 121.86% | |
| — | (221.84%) | (209.81%) | (150.52%) | (187.95%) | (47.00%) | (292.93%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | (492.24%) | 2,335.45% | (312.10%) | (605.93%) | (231.75%) | 290.36% |
Average Days of Receivables |
— | 23.23 | 57.86 | 14,946.98 | 191.13 | 990.89 | 75,737.50 |
Research and Development Expense of Revenue |
— | 38.06% | 44.03% | 29,470.99% | 3,671.61% | 7,884.92% | 745,950.00% |
Selling, General and Administrative Expense of Revenue |
— | 79.25% | 83.49% | 37,060.49% | 5,878.03% | 12,471.15% | 932,725.00% |
Intangible Assets out of Total Assets |
0.00 | 0.10 | 0.11 | 0.04 | 0.06 | 0.11 | 0.19 |
Share Based Compensation of Revenue |
— | 0.00% | 1.65% | 5,088.89% | 959.26% | 2,558.69% | 411,875.00% |
Graham Net Nets |
— | 1.28 | 1.28 | (0.52) | (0.27) | (6.56) | (5.41) |
Graham Number |
— | 0.00 | 0.00 | 6,073.16 | 1,421.94 | 393.62 | 245.59 |
Earnings Yield |
— | (140.00%) | (140.00%) | (227.59%) | (134.45%) | (218.72%) | (313.45%) |
Free Cash Flow Yield |
— | (216.20%) | (216.20%) | (64.79%) | (48.50%) | (363.44%) | (231.63%) |
Revenue per Share |
— | 69.30 | 7,383.85 | 1.47 | 3.24 | 0.40 | 0.00 |
Operating CF per Share |
— | (35.27) | (5,442.26) | (1,505.40) | (435.48) | (84.37) | (30.75) |
Capex per Share |
— | 0.00 | (191.03) | (35.16) | (2.22) | (1.04) | (0.06) |
Free Cash Flow per Share |
— | (35.27) | (5,633.28) | (1,540.55) | (437.70) | (85.41) | (30.81) |
Cash per Share |
— | 37.48 | 1,694.46 | 836.29 | 229.84 | 39.93 | 9.64 |
Shareholders Equity per Share |
— | (20.02) | (4,301.23) | (971.79) | (220.95) | (133.97) | (64.30) |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (20.02) | (4,301.23) | (971.79) | (220.95) | (133.97) | (64.30) |
Free Cash Flow |
— | (65.13) | (109.85) | (169.61) | (168.34) | (65.21) | (48.59) |
Working Capital |
— | 10.89 | (25.69) | 53.67 | 37.17 | 14.81 | (43.90) |
Capital Expenditures |
— | (4.83) | (3.72) | (3.87) | (0.85) | (0.79) | (0.09) |
Net Current Asset Value |
— | (64.42) | (110.95) | (135.10) | (95.04) | (117.70) | (113.56) |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | 0.00 | 0.03 | 23.90 | 0.69 | 2.60 | 23.00 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||
Depreciation/Fixed assets |
— | 0.40 | 0.40 | 0.63 | 0.82 | 1.41 | 1.87 |
Cash ROIC |
— | (62.04%) | 232.97% | (116.69%) | (129.67%) | (114.60%) | 119.98% |
Accounts Receivable Turnover |
— | 8.26 | 9.30 | 0.01 | 0.34 | 0.41 | 0.00 |
Accounts Payable Turnover |
— | 6.87 | 7.50 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 9.93 | 10.83 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
— | 43.74 | 57.22 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 30.19 | 39.72 | 3,101.48 | 0.00 | 0.00 | — |
Average Receivables |
— | 15.48 | 15.48 | 14.73 | 3.64 | 0.74 | 0.83 |
Average Payables |
— | 13.39 | 13.39 | 16.57 | 13.04 | 6.16 | 3.22 |
Average Inventory |
— | 9.28 | 9.28 | 11.58 | — | — | — |
Average Assets |
— | 58.20 | 109.06 | 128.08 | 131.64 | 81.18 | 42.37 |
Average Common Equity |
— | (60.48) | (60.48) | (95.49) | (95.98) | (93.63) | (101.85) |
Columns are period end dates